Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
JW Lifescience Corporation (234080.KS)
KRW11,220.00
+70.00 (+0.63%)
KR KSC Healthcare Medical - Pharmaceuticals
Address
28, Hanjin 1-gil 31720
Dangjin-si, KR
Dangjin-si, KR
CEO
Seong-Nam Cha
Website
jw-lifescience.co.kr
IPO
2016-10-27
ISIN KR7234080000
Description
JW Life Science Corp. manufactures intravenous fluids. Its products include basic IV, nutrition, special fluids, irrigation agents and dialysis solutions. The company was founded on May 10, 1994 and is headquartered in Dangjin-si, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW11,220.00
+70.00 (+0.63%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
40.3K
Beta
0.24
Float Shares
8.56M
Free Float %
55.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.73% | -6.12% | -12.14% | -14.39% | -24.11% | -11.32% | -6.81% | -8.39% | -38.76% | -47.10% | -47.10% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
11,220.00
DCF (Unlevered)
63,758.92
+468.3%
DCF (Levered)
54,845.87
+388.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.99
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+15.9% ★ Q1'26: -16.6% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-35.0% Q1'26: +9.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+11.5% Q1'26: +17.1% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+12.9% ★ Q1'26: +14.7% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+11.5% ★ Q1'26: +10.9% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-0.3% ★ Q1'26: +2.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.98× Q1'26: 0.75× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
143.60B
est: 142.85B (+0.5%)
|
155.23B
est: 156.60B (-0.9%)
|
170.22B
est: 168.00B (+1.3%)
|
183.52B
est: 186.00B (-1.3%)
|
169.82B
est: 207.00B (-18.0%)
|
188.93B
est: 186.60B (+1.2%)
|
206.86B
est: 207.30B (-0.2%)
|
222.48B
est: 220.40B (+0.9%)
|
257.83B
est: 243.50B (+5.9%)
|
273.90B
273.90B – 273.90B
+12.5% YoY
|
293.80B
293.80B – 293.80B
+7.3% YoY
|
315.30B
315.30B – 315.30B
+7.3% YoY
|
| EBITDA |
34.95B
est: 35.67B (-2.0%)
|
34.64B
est: 39.10B (-11.4%)
|
41.66B
est: 41.95B (-0.7%)
|
37.57B
est: 46.44B (-19.1%)
|
37.57B
est: 51.68B (-27.3%)
|
43.73B
est: 46.59B (-6.1%)
|
50.83B
est: 51.76B (-1.8%)
|
76.82B
est: 54.80B (+40.2%)
|
51.41B
est: 60.54B (-15.1%)
|
68.10B
68.10B – 68.10B
+12.5% YoY
|
73.05B
73.05B – 73.05B
+7.3% YoY
|
78.39B
78.39B – 78.39B
+7.3% YoY
|
| EBIT |
23.85B
est: 25.12B (-5.1%)
|
23.57B
est: 27.53B (-14.4%)
|
30.06B
est: 29.54B (+1.8%)
|
25.34B
est: 32.70B (-22.5%)
|
24.35B
est: 36.39B (-33.1%)
|
28.80B
est: 32.81B (-12.2%)
|
35.32B
est: 36.45B (-3.1%)
|
61.09B
est: 38.35B (+59.3%)
|
33.30B
est: 42.37B (-21.4%)
|
47.66B
47.66B – 47.66B
+12.5% YoY
|
51.12B
51.12B – 51.12B
+7.3% YoY
|
54.86B
54.86B – 54.86B
+7.3% YoY
|
| Net Income |
16.78B
est: 16.81B (-0.2%)
|
15.82B
est: 14.57B (+8.6%)
|
21.94B
est: 21.63B (+1.4%)
|
17.30B
est: 26.17B (-33.9%)
|
12.91B
est: 29.96B (-56.9%)
|
14.96B
est: 17.05B (-12.2%)
|
28.14B
est: 22.87B (+23.1%)
|
43.99B
est: 31.81B (+38.3%)
|
28.61B
est: 28.78B (-0.6%)
|
27.33B
27.33B – 27.33B
-5.0% YoY
|
29.16B
29.16B – 29.16B
+6.7% YoY
|
31.28B
31.28B – 31.28B
+7.3% YoY
|
| SGA |
7.51B
est: 7.37B (+2.0%)
|
7.40B
est: 8.08B (-8.4%)
|
8.09B
est: 8.67B (-6.7%)
|
7.60B
est: 9.59B (-20.7%)
|
8.29B
est: 10.68B (-22.3%)
|
8.76B
est: 9.63B (-9.0%)
|
15.10B
est: 10.69B (+41.2%)
|
10.74B
est: 12.82B (-16.2%)
|
19.17B
est: 14.16B (+35.4%)
|
15.93B
15.93B – 15.93B
+12.5% YoY
|
17.09B
17.09B – 17.09B
+7.3% YoY
|
18.34B
18.34B – 18.34B
+7.3% YoY
|
| EPS |
1,059.52
est: 1,085.75 (-2.4%)
|
999.14
est: 941.00 (+6.2%)
|
1,385.48
est: 1,397.00 (-0.8%)
|
1,092.55
est: 1,690.00 (-35.4%)
|
828.84
est: 1,935.00 (-57.2%)
|
966.21
est: 1,101.00 (-12.2%)
|
1,817.55
est: 1,477.00 (+23.1%)
|
2,842.77
est: 2,059.00 (+38.1%)
|
1,847.38
est: 1,863.00 (-0.8%)
|
1,769.00
1,769.00 – 1,769.00
-5.0% YoY
|
1,888.00
1,888.00 – 1,888.00
+6.7% YoY
|
2,025.00
2,025.00 – 2,025.00
+7.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
35.75B
OE per share TTM
2,306.99
Owner's Yield
19.87%
Maintenance CapEx ratio
174.12%
Maint CapEx / Avg PPE
65.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 7 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.00% | 36.9K | 0.15% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 9.7K | 0.44% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 129.0K | 0.39% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 27.8K | 0.46% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 59.4K | 0.28% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 27.3K | 0.29% |
| 7 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 240.23 | 0.56% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
104.40M
Shares Outstanding
15.48M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jeong Yeol Noh | Executive Director & Head of HP Research Center | — | — |
| Na Sook Hee | Executive Director | — | — |
| Sungnam Cha | Chief Executive Officer & Director | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 234080.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
